TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
INVA

Innoviva Inc

Healthcare · Biotechnology

20.20$ -3.5% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement INVA
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
88.9% 4.9% 1.0% 0.6% 0.0% – 0.5% 3.5% 4.2% 13.7% 10.2% 27.7%
11.1% 95.1% 99.0% 100.0% 100.0% 100.0% 0.1% 100.0% 95.8% 86.3% 89.8% 72.3%
88.9% 4.9% 1.0% 0.6% 0.0% 0.2% 0.5% 0.1% 12.5% 10.9% 3.8% 7.2%
413.4% 36.6% 17.4% 14.9% 8.7% 5.6% 4.1% 4.1% 19.2% 28.8% 32.3% 26.7%
413.4% 41.5% 17.4% 15.5% 8.7% 5.6% 4.7% 4.3% 33.4% 49.6% 43.3% 33.8%
-402.3% 58.5% 81.6% 84.5% 91.3% 94.4% 95.3% 95.7% 62.5% 36.7% 46.5% 38.5%
437.5% 96.0% 39.2% 20.1% 9.2% 7.1% 5.4% 4.9% 4.8% 6.2% 6.2% 3.9%
-871.9% -34.8% 44.6% 61.8% 80.6% 89.2% 105.2% 113.6% 86.6% 62.5% 10.4% 76.9%
1,595.3% 93.3% 0.1% 0.0% -75.1% 16.1% 17.9% 19.5% 20.1% 4.6% 3.9% 13.1%
-1,997.7% -34.8% 44.6% 61.8% 151.4% 60.3% 66.6% 67.8% 64.6% 57.9% 6.5% 63.8%
-290.1% 84.4% 92.0% 88.3% 90.7% 88.8% 94.1% 92.2% 93.1% 75.7% 23.8% 90.3%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?